Oklo Proposes $25M All-Stock Acquisition of Atomic Alchemy to Enter Radioisotope Market
Photo Credit: Oklo Inc.
Key Points
- Oklo Inc. (NYSE: OKLO) has signed a letter of intent to acquire Atomic Alchemy Inc. for $25 million in an all-stock transaction, subject to customary adjustments.
- The proposed deal extends a strategic partnership between the two companies announced earlier in 2024, combining Oklo’s fast reactor and fuel recycling technologies with Atomic Alchemy’s radioisotope production expertise.
- Atomic Alchemy’s proprietary VIPR technology and Neutron Transmutation Doping (NTD) capabilities for semiconductors are key technology assets in the acquisition.
- The radioisotope market is projected to reach $55.7 billion by 2026, with current global supply dominated by Russia and constrained by aging reactor infrastructure.
- Oklo expects to begin generating revenue from radioisotope production following closing, with initial revenues anticipated before the first dedicated radioisotope production reactors are completed.
Browse our Uranium Stocks List for a comprehensive overview of publicly traded Uranium mining companies.
Deal Overview
Oklo Inc. announced on November 14, 2024 that it had signed a letter of intent to acquire Atomic Alchemy Inc., a U.S.-based company specialising in radioisotope production. The proposed acquisition is structured as an all-stock transaction valued at $25 million, subject to customary adjustments.
The announcement formalises and deepens a strategic partnership between the two companies that was first disclosed earlier in 2024. Oklo’s fast reactor and fuel recycling technologies produce valuable coproducts, including radioisotopes, and the proposed acquisition is designed to combine these capabilities with Atomic Alchemy’s radioisotope production expertise.
Atomic Alchemy was founded to build a domestic U.S. radioisotope supply chain using its proprietary Versatile Isotope Production Reactor (VIPR) technology. The company operates a vertically integrated model combining fuel recycling with scalable isotope production, and has positioned itself as a solution to chronic global supply shortages of medical and industrial radioisotopes.
What are Radioisotopes?
Radioisotopes are unstable atomic nuclei that emit radiation as they decay. They are essential across medicine (cancer treatment, diagnostic imaging), industry, research, and defense. Many life-saving medical radioisotopes have very short half-lives and must be produced continuously near end users, making a resilient domestic supply chain strategically important.
Transaction Terms
The proposed acquisition is structured as a $25 million all-stock transaction, subject to customary adjustments. All Oklo shares issued to existing Atomic Alchemy shareholders are expected to be subject to multi-year lock-up agreements.
| Term | Detail |
|---|---|
| Acquirer | Oklo Inc. (NYSE: OKLO) |
| Target | Atomic Alchemy Inc. |
| Transaction Type | Proposed acquisition (letter of intent signed) |
| Transaction Value | $25 million (subject to customary adjustments) |
| Consideration | All-stock (Oklo shares) |
| Lock-up | Multi-year lock-up on all shares issued to Atomic Alchemy shareholders |
| Impact on 2024 Outlook | Not expected to impact Oklo’s previously announced 2024 outlook |
| Operating Cost Impact | Minimal immediate impact on Oklo’s operating cost structure at closing |
| Status | Letter of intent; definitive agreement and closing conditions to follow |
Oklo stated that the transaction is not expected to have a material impact on its operating cost structure upon closing, and that its previously communicated 2024 financial outlook remains unchanged. The all-stock structure preserves Oklo’s cash position while the multi-year lock-ups align Atomic Alchemy shareholders with Oklo’s long-term performance.
Oklo indicated it expects to begin generating revenue from radioisotope activities following the close of the transaction, with initial revenues anticipated before the construction of dedicated radioisotope production reactors is completed.
Strategic Rationale
Oklo’s fast fission reactors and fuel recycling operations produce radioisotopes as coproducts of the nuclear process. The company has framed the Atomic Alchemy acquisition as a way to monetise these coproducts, creating a complementary revenue stream alongside its primary power generation and fuel recycling businesses.
“The proposed acquisition is expected to enable Oklo to significantly broaden its impact, as our fast reactor and fuel recycling technologies allow us to produce radioisotopes as a coproduct. By incorporating radioisotope production into our fuel recycling process, Oklo is establishing a complementary revenue stream and contributing to a more resilient radioisotope supply chain.”— Jacob DeWitte, Co-founder and CEO, Oklo Inc.
The deal also targets sectors beyond Oklo’s existing power and fuel focus, including biotech, pharmaceuticals, space, defense, and semiconductors. Atomic Alchemy’s Neutron Transmutation Doping (NTD) capability is cited as a potentially transformative technology for the semiconductor industry.
What is Neutron Transmutation Doping (NTD)?
NTD is a process that uses neutrons produced in a nuclear reactor to convert silicon atoms into phosphorus through nuclear transmutation, uniformly doping an entire semiconductor ingot before it is cut into wafers. Oklo describes it as a “gold-standard” method that produces more uniform dopant distribution than conventional techniques, can process large volumes in batches, and allows fine-tuning of dopant quantities.
Oklo also highlighted the potential for the acquisition to accelerate fuel availability for its Aurora powerhouses. The key highlights note that radioisotopes can “enhance the economics of nuclear fuel recycling and accelerate fuel availability for Oklo’s powerhouses through the sales of high-value radioisotopes.”
“I deeply believe in the importance of abundance and reliable energy for the future, and Oklo’s proposed acquisition of Atomic Alchemy opens the door for nuclear technology to play an even greater role in solving critical energy, medical, and industrial challenges.”— Sam Altman, Chairman and Board Member, Oklo Inc.
Market Context
The global radioisotope market is projected to reach $55.7 billion by 2026, according to Research Nester, with demand expected to grow significantly over the following decade. Demand is driven by expanding applications in cancer treatment, diagnostic imaging, and a range of industrial and research uses.
Supply has struggled to keep pace with demand. The British Institute of Radiology has highlighted that aging reactor infrastructure and a fragmented global supply chain are the primary constraints, with the current market dominated by Russia. Oklo aims to address this gap through reliable, U.S.-based radioisotope production facilities that leverage its core clean energy and fuel recycling technologies.
By establishing domestic U.S. production using its fast reactor and fuel recycling infrastructure, Oklo intends to combine Atomic Alchemy’s versatile irradiation reactor technologies with its own fast reactor capabilities to address urgent supply shortages in life-saving medical radioisotopes and advanced industrial applications.